Skip to main content
. 2017 Dec 6;10:5805–5816. doi: 10.2147/OTT.S150349

Table 2.

HRs and 95% CIs of patient survival or cancer progression relating to CD82 expression in eligible studies

First author, publication year Assay method Cutoff point Case number
OS
DFS/RFS/PFS
High expression Low expression HR (95% CI) (U/M) p-value HR (95% CI) (U/M) p-value
Zhu, 201710 IHC IRS scores ≥3 (range of 0–12) 65 139 0.302 (0.184–0.497)M <0.001 NM NM
Lu, 201612 IHC IRS scores ≥3 (range of 0–12) 134 191 0.648 (0.492–0.854)M 0.002 NM NM
Singh, 201611 qRT-PCR NM 46 29 0.66 (0.26–1.68)Ue 0.047 NM NM
Guo, 201516,a IHC >10% of tumor cells stained 28 100 1.07 (0.22–5.24)Ue <0.05 NM NM
Guo, 201516,b qRT-PCR NM 40 88 0.62 (0.19–1.98)Ue <0.05 NM NM
Wu, 201532 IHC IRS scores ≥3 (range of 0–12) 56 118 0.430 (0.269–0.687)M <0.001 NM NM
Han, 201536 IHC IRS scores ≥3 (range of 0–12) 137 188 0.617 (0.462–0.823)M 0.001 NM NM
Yu, 201413 IHC IRS scores ≥3 (range of 0–12) 34 49 0.226 (0.094–0.545)M 0.001 0.278 (0.119–0.647)M 0.003
Kwon, 201419 IHC .0% of tumor cells stained 98 546 1.513 (1.057–2.165)M 0.024 f f
Tang, 201414,c IHC IRS scores ≥8 (range of 0–12) 114 303 0.42 (0.29–0.63)M 0.0000147 NM NM
Tang, 201414,d IHC IRS scores ≥8 (range of 0–12) 114 303 0.59 (0.36–0.96)M 0.029 NM NM
Zhang, 201337 IHC Accumulated points ≥80 52 48 0.54 (0.27–1.05)Ue NM NM NM
Zhang, 201338 WB NM 43 43 0.36 (0.17–0.77)Ue NM NM NM
Wu, 201215 IHC IRS scores >1 (range of 0–12) 19 31 0.039 (0.007–0.236)M 0.00 NM NM
Knoener, 201233 IHC IRS scores ≥3 (range of 0–12) 168 103 0.77 (0.55–1.07)Ue 0.2305 NM NM
Guo, 200939 IHC >10% of tumor cells stained 21 59 0.81 (0.28–2.32)Ue 0.022 NM NM
Protzel, 200834 IHC >50% of tumor cells stained 17 13 0.34 (0.02–4.90)Ue 0.0042 NM NM
Miyazaki, 200540 IHC Ki index ≥39 48 43 0.48 (0.22–1.03)Ue 0.0023 NM NM
Leavey, 200517 IHC NM 16 31 1.14 (0.27–4.81)Ue 0.28 0.99 (0.35–2.85)Ue 0.24
Farhadieh, 200441 IHC >10% of tumor cells stained 15 42 0.52 (0.27–1.01)M 0.053 0.4 (0.2–0.8)M 0.009
Goncharuk, 200442 IHC Median 77 27 0.47 (0.23–0.97)Ue 0.034 NM NM
Su, 200450 IHC >50% of tumor cells stained 54 33 NM NM 0.255 (0.111–0.588)M 0.0013
Hashida, 200318 IHC Scores ≥120 (range of 0–300) 63 83 0.903 (0.297–2.747)M 0.858 1.054 (0.431–2.577)M 0.909
Imai, 200243 qRT-PCR NM 25 18 0.51 (0.06–4.38)Ue NM NM NM
Schindl, 200144 IHC Scores ≥4 (range of 3–7) 48 59 0.45 (0.22–0.92)M 0.0282 0.3 (0.09–0.93)M 0.0372
Miyazaki, 200045 IHC >10% of tumor cells stained 36 19 0.41 (0.17–1.00)Ue 0.024 NM NM
Yang, 200046 IHC >5% of tumor cells stained 36 36 0.72 (0.20–2.61)Ue NM NM NM
Sho, 199847 IHC >50% of tumor cells stained 15 25 1.16 (0.29–4.64)Ue 0.018 NM NM
Huang, 199848 IHC HSCORE >50 44 65 0.442 (0.109–1.789)M 0.2528 0.360 (0.149–0.870)M 0.0234
Higashiyama, 199735 IHC >50% of tumor cells stained 65 135 0.700 (0.502–0.976)M 0.037 f f
Adachi, 199649 qRT-PCR Gene conservation rate value >1.2 35 116 0.416 (0.175–0.986)M 0.046 NM NM

Notes: The source of HR and 95% CI was extracted from survival curves or article reports.

a,b

Data extracted from one study due to different assay method (IHC and qRT-PCR).

c,d

Data extracted from one study due to different follow-up time (120 and 60 months).

e

HR calculated from survival curves.

f

Excluded due to its heterogeneity and publication bias.

Abbreviations: IHC, immunohistochemistry; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; WB, western-blot; NM, not mentioned; IRS, immunoreactivity score; HSCORE, the intensity and respective percentage cells that stain at each intensity were multiplied to reach a HSCORE that ranged from 0 to 300; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; PFS, progression-free survival; SC, survival curve; HR, hazard ratio; CI, confidence interval; U, univariate analysis; M, multivariate analysis.